Core Viewpoint - 旺山旺水-B (02630) experienced a significant drop of over 18% on its second day of trading after a previous surge of over 145%, with the current stock price still approximately double its IPO price of 33.37 HKD [1] Company Overview - 旺山旺水 was established in 2013 and is a biopharmaceutical company focusing on three main therapeutic areas: neuropsychiatry, reproductive health, and viral infections [1] - As of October 21, 2025, the company has developed a diversified pipeline of nine innovative products, with two in commercialization, four in clinical stages, and three in preclinical stages [1] - In addition to its innovative drug pipeline, the company is also involved in the generic drug sector, with three products either commercialized or nearing commercialization [1] - The company's two core products are LV232 and TPN171 [1] Financial Performance - For the fiscal years 2023 and 2024, as well as the first four months of 2024 and 2025, the company reported revenues of 200 million RMB, 11.832 million RMB, 3.224 million RMB, and 12.958 million RMB, respectively [1] - In 2024, the company recorded a net loss of 218 million RMB, compared to a net profit of 6.427 million RMB in 2023, with the fluctuation attributed to a decline in revenue [1]
旺山旺水-B上市次日回吐逾18% 仍较招股价高约一倍